Ultragenyx Engages in Key Investor Conferences This Fall
NOVATO, Calif. — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a leading biopharmaceutical company dedicated to developing innovative therapies for serious rare and ultra-rare genetic diseases, has announced its participation in several important investor conferences this September.
Upcoming Investor Conferences
Ultragenyx is proud to take part in three significant conferences, providing an opportunity for company executives to connect with investors and discuss the company's growth and development in the biopharmaceutical sector.
Cantor Global Healthcare Conference 2025
The first event is the Cantor Global Healthcare Conference, where on September 4, 2025, Eric Crombez, M.D., Chief Medical Officer, along with Howard Horn, Chief Financial Officer, will participate in a fireside chat. They will also engage in one-on-one meetings, offering insights into the company’s latest advancements and strategies in rare disease treatments.
Morgan Stanley's Annual Global Healthcare Conference
Next up, on September 9, 2025, Ultragenyx will join the Morgan Stanley's 23rd Annual Global Healthcare Conference. Eric Crombez will once again represent the company in a fireside chat, followed by personalized meetings that allow for in-depth conversations with investors about the promising pipeline.
Bank of America Global Healthcare Conference
The third conference, the Bank of America Global Healthcare Conference on September 23, 2025, will also feature Eric Crombez. This session will include a fireside chat accompanied by one-on-one meetings, solidifying the company’s commitment to transparency and investor relations.
Live Webcasts and Archiving
Investors and interested parties can access the live and archived webcasts of the fireside chats on the company’s website. This resource is a great way to stay updated with Ultragenyx's discussions surrounding their innovative approaches and the future of their therapeutic offerings.
About Ultragenyx
Ultragenyx is unwavering in its commitment to providing novel therapeutic options for patients facing serious rare and ultra-rare genetic conditions. With a robust portfolio of approved therapies and promising product candidates, the company addresses unmet medical needs through targeted, biology-driven approaches.
Leading Ultragenyx is a skilled management team, seasoned in the nuances of rare disease therapeutics development and commercialization. Their strategic focus is on efficient and rapid drug development processes, ensuring that safe and effective treatments reach patients in a timely manner.
Contact Information
For further inquiries, investors can reach out to Joshua Higa at ir@ultragenyx.com.
Frequently Asked Questions
What is the purpose of Ultragenyx's participation in investor conferences?
Ultragenyx participates in investor conferences to engage with investors, discuss company developments, and share insights about their therapeutic advancements.
Who is representing Ultragenyx at the Cantor Global Healthcare Conference?
Eric Crombez, M.D., and Howard Horn, CFO, will represent Ultragenyx at the Cantor Global Healthcare Conference on September 4, 2025.
How can the public access the conference discussions?
Live and archived webcasts of the fireside chats will be available on Ultragenyx's official website.
What does Ultragenyx focus on in its biopharmaceutical endeavors?
The company specializes in developing therapies for serious rare and ultra-rare genetic diseases, aiming to meet high unmet medical needs.
What are the benefits of Ultragenyx's approach to drug development?
Ultragenyx emphasizes time- and cost-efficient drug development, which helps in promptly delivering safe and effective therapies to patients.
